This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Perilous Reversal Watch: IsoRay (ISR)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified IsoRay ( ISR) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified IsoRay as such a stock due to the following factors:

  • ISR has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $15.2 million.
  • ISR has traded 126,053 shares today.
  • ISR is down 4.5% today.
  • ISR was up 5.5% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in ISR with the Ticky from Trade-Ideas. See the FREE profile for ISR NOW at Trade-Ideas

More details on ISR:

IsoRay, Inc develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases primarily in the United States.

The average volume for IsoRay has been 9.4 million shares per day over the past 30 days. IsoRay has a market cap of $97.2 million and is part of the health care sector and health services industry. The stock has a beta of -2.64 and a short float of 11.6% with 0.73 days to cover. Shares are up 368% year-to-date as of the close of trading on Tuesday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreetRatings.com Analysis:

TheStreet Quant Ratings rates IsoRay as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, poor profit margins and weak operating cash flow.

Highlights from the ratings report include:

  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Biotechnology industry and the overall market, ISORAY INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • The gross profit margin for ISORAY INC is currently extremely low, coming in at 14.38%. Despite the low profit margin, it has increased significantly from the same period last year. Despite the mixed results of the gross profit margin, ISR's net profit margin of -85.43% significantly underperformed when compared to the industry average.
  • Net operating cash flow has decreased to -$0.85 million or 47.38% when compared to the same quarter last year. Despite a decrease in cash flow ISORAY INC is still fairing well by exceeding its industry average cash flow growth rate of -66.38%.
  • ISORAY INC has improved earnings per share by 33.3% in the most recent quarter compared to the same quarter a year ago. Stable earnings per share over the past two years indicate the company has managed its earnings and share float. We anticipate this stability to falter in the coming year and, in turn, the company to deliver lower earnings per share than the prior full year. During the past fiscal year, ISORAY INC continued to lose money by earning -$0.11 versus -$0.12 in the prior year. For the next year, the market is expecting a contraction of 18.2% in earnings (-$0.13 versus -$0.11).
  • The net income growth from the same quarter one year ago has exceeded that of the Biotechnology industry average, but is less than that of the S&P 500. The net income increased by 19.7% when compared to the same quarter one year prior, going from -$1.16 million to -$0.93 million.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
Submit an article to us!

Markets

DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs